Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer
Lung Cancer, 07/18/2012
Garon EB – Recent high profile trials have been designed to assess progression–free survival (PFS) using a randomized discontinuation design and disease control rate after 8weeks of treatment. With a series of recent advances toward increasingly personalized biomarker–directed anticancer therapies, the appropriateness of the traditional regulatory approach has been questioned.



